Education
About Us
Working with TipRanks
Follow Us
Everest Medicines Ltd. (HK:1952)
:1952
RESEARCH TOOLSreports
Total Valuation
Everest Medicines Ltd. has a market cap or net worth of HK$15.22B. The enterprise value is HK$14.60B.
Market CapHK$15.22B
Enterprise ValueHK$14.60B
Share Statistics
Everest Medicines Ltd. has 326.58M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding326.58M
Owned by Insiders
Owned by Instutions
Financial Efficiency
Everest Medicines Ltd.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per EmployeeHK$409,387.97
Profits Per Employee-HK$1,426,862.406
Employee Count665
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Everest Medicines Ltd. is ―. Everest Medicines Ltd.’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Everest Medicines Ltd. had revenue of HK$272.24M and earned -HK$948.86M in profits. Earnings per share was -HK$2.98.
RevenueHK$272.24M
Gross ProfitHK$204.27M
Operating Income-HK$988.42M
Pretax Income-HK$948.86M
Net Income-HK$948.86M
EBITDA-925.48M
Earnings Per Share (EPS)-2.98
Cash Flow
In the last 12 months, operating cash flow was -HK$548.49M and capital expenditures -HK$81.57M, giving a free cash flow of -HK$630.06M billion.
Operating Cash Flow-HK$548.49M
Free Cash Flow-HK$630.06M
Free Cash Flow per Share-HK$1.93
Dividends & Yields
Everest Medicines Ltd. pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.11
52-Week Price Change105.68%
50-Day Moving Average49.76
200-Day Moving Average35.35
Relative Strength Index (RSI)43.62
Average Volume (3m)6.15M
Important Dates
Everest Medicines Ltd. upcoming earnings date is Sep 2, 2025, Before Open.
Last Earnings DateMar 26, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend Date―
Financial Position
Everest Medicines Ltd. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Everest Medicines Ltd. has paid HK$15.17M in taxes.
Income TaxHK$15.17M
Effective Tax Rate―
Enterprise Valuation
Everest Medicines Ltd. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Everest Medicines Ltd. has HK$2.35B in cash and marketable securities with HK$0.00 in debt, giving a net cash position of -HK$2.35B billion.
Cash & Marketable SecuritiesHK$2.35B
Total DebtHK$0.00
Net Cash-HK$2.35B
Net Cash Per Share-HK$7.19
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Everest Medicines Ltd. is HK$48.32, which is 11.43% higher than the current price. The consensus rating is Hold
Price TargetHK$48.32
Price Target Upside3.69%
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast461.36%
EPS Growth Forecast-16.43%